CA2767614C - Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes - Google Patents

Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes Download PDF

Info

Publication number
CA2767614C
CA2767614C CA2767614A CA2767614A CA2767614C CA 2767614 C CA2767614 C CA 2767614C CA 2767614 A CA2767614 A CA 2767614A CA 2767614 A CA2767614 A CA 2767614A CA 2767614 C CA2767614 C CA 2767614C
Authority
CA
Canada
Prior art keywords
dose
administered
hours
administration
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2767614A
Other languages
English (en)
Other versions
CA2767614A1 (fr
Inventor
Ronald Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrevus Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of CA2767614A1 publication Critical patent/CA2767614A1/fr
Application granted granted Critical
Publication of CA2767614C publication Critical patent/CA2767614C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux schémas posologiques pour le traitement et la prévention d?infections bactériennes à l?aide d?acide fusidique. Il a été découvert que l?utilisation d?une dose de charge élevée d?acide fusidique, suivie de doses d?entretien modérées du médicament, prévient le développement de souches de bactéries résistant au médicament, augmente le spectre efficace du médicament, et évite les nausées et vomissements associés à un traitement prolongé avec des quantités élevées du médicament.
CA2767614A 2009-07-13 2009-07-13 Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes Active CA2767614C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/050353 WO2011008193A1 (fr) 2009-07-13 2009-07-13 Schémas posologiques de l’acide fusidique pour le traitement d’infections bactériennes

Publications (2)

Publication Number Publication Date
CA2767614A1 CA2767614A1 (fr) 2011-01-20
CA2767614C true CA2767614C (fr) 2019-01-15

Family

ID=43449613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2767614A Active CA2767614C (fr) 2009-07-13 2009-07-13 Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes

Country Status (2)

Country Link
CA (1) CA2767614C (fr)
WO (1) WO2011008193A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (fr) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Formulations parentérales pour l'administration d'antibiotiques macrolides
WO2014152326A1 (fr) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Procédés pour traiter des maladies respiratoires et formulations pour la mise en œuvre de ceux-ci
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
US9345717B2 (en) 2013-09-25 2016-05-24 Zavante Therapeutics, Inc. Method for improving drug treatments in mammals
CN116650399B (zh) * 2023-04-13 2025-09-05 福元药业有限公司 一种夫西地酸乳膏及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230656B1 (hu) * 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition

Also Published As

Publication number Publication date
CA2767614A1 (fr) 2011-01-20
WO2011008193A1 (fr) 2011-01-20

Similar Documents

Publication Publication Date Title
CA2767614A1 (fr) Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes
US12514899B2 (en) Methods of treatment using single doses of oritavancin
US8450300B2 (en) Fusidic acid dosing regimens for treatment of bacterial infections
US20130164351A1 (en) Methods of treating bacterial infections through pulmonary delivery of fusidic acid
US20110301132A1 (en) Methods of treating urethritis and related infections using fusidic acid
CA2760159C (fr) Procedes de traitement d'infections bacteriennes a l'aide d'oritavancine
CN109952103A (zh) 用于治疗细菌感染的系统和方法
US20190307744A1 (en) Pharmaceutical compositions comprising clofazimine analog compound b746 or clofazimine analog compound b826
JP2997202B2 (ja) 局所的眼科用途の為のトブラマイシンとステロイドの組合わせ
US9775878B2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
CN121752252A (zh) 含有mTOR抑制剂和脂质的组合物
RU2452476C2 (ru) Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
US20170119793A1 (en) Compositions and methods for treating bone and joint infections
US20070072814A1 (en) Method and means of modulating lipid metabolism

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140623

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240712

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240916

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20241125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251023

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260225

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225